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REVIEw
the complication of coinfection
Lesley Pasman
Department of Immunobiology, Yale Graduate School of Arts & Sciences, New Haven,
Connecticut
Infectious disease remains one of the largest burdens on humankind. Even with modern
medical and public health standards, infectious disease remained the No. 1 killer worldwide
at the turn of the century. Often, the most costly disease burdens come from multiple infec-
tions at once, i.e., coinfection. Influenza, an annual infection often considered relatively
harmless, can increase susceptibility to both deadly bacterial pneumonia and childhood ear
infections. Major health threat HIV rarely kills a patient on its own, but instead allows for op-
portunistic infections and re-emergence of infections such as tuberculosis. what generates
these unique relationships is not well understood; herein, we examine in detail three types
of coinfection and the unique interactions between infectious agents as well as with the host
in each setting. we also begin to address how we may aid further understanding of coin-
fection and what questions need to be addressed to help direct future treatments. 
IntroductIon
Of the various assaults our bodies face
throughout our lifetimes, infectious disease
remains one of the main killers across the
globe. At the turn of the century, infectious
disease  classified  as  the  second  leading
killer in the world, behind only cardiovas-
cular diseases [1]. However, in most scien-
tific  and  medical  investigations  of
prominent infections, these causal agents
are studied in isolation. The immune state
of the infected host is largely assumed to be
a blank slate, when this is often not the case.
Our bodies are in constant contact with the
outside environment and, therefore, at con-
stant risk of infection. It is consequentially
predictable that many individuals may ex-
perience combined infections. These com-
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bial infection, secondary infection, Mtbbinations, called polymicrobial or coinfec-
tion, represent some of our most difficult in-
fectious  diseases  to  battle,  even  as  they
remain largely understudied in their com-
bined state. 
Below, we examine three common set-
tings that can fall under the coinfection um-
brella, how this situation affects our immune
system’s handling of each infection, and how
we can better address these infections to in-
crease  our  understanding  of  their  natural
course and perhaps also improve medical
treatment.
coInfectIon, a defInItIon
There are several different scenarios in
the umbrella of coinfection. Infections can
be concurrent or closely sequential, as well
as involving both acute and chronic infec-
tions. Each of these combinations has repre-
sentations in modern health care. A major
example of concurrent acute infections is the
increased susceptibility to respiratory bacte-
rial infection during an ongoing influenza
infection; in fact, this susceptibility is the
main cause of death by influenza infection,
especially in the elderly [2-4]. Through com-
plications  with  bacterial  pneumonia,  in-
fluenza infection kills on average 20,000
individuals a year [2]. The immune response
can also remain suppressed following reso-
lution of infection, thus allowing secondary
infection in an altered host state. This can be
exemplified by childhood ear infection and
is also seen as a variation of secondary bac-
terial pneumonia after influenza [5]. Lastly,
an ongoing chronic infection can be compli-
cated by and increase susceptibility for con-
current acute infections. A prime example
plaguing our current health care is human
immunodeficiency virus (HIV†) infection,
as patients ultimately succumb to oppor-
tunistic acute infections that can take hold
only due to the overwhelming immune sup-
pression caused by the virus [6]. 
Concurrent acute: bacterial pneumonia
complicating flu infection
Although we have annual vaccinations,
influenza virus is one of the main infectious
disease killers worldwide [1]. Of the 25 per-
cent of deaths caused by infectious diseases,
acute respiratory infections (for the majority,
influenza and pneumonia) constitute 30 per-
cent. Even in the years of mild seasonal flu,
this infection remains a threat to the elderly
[3]. Yet this virus rarely kills on its own. In
most cases, death by influenza virus actually
occurs due to the onset of bacterial pneumo-
nia. Often, these are bacterial species that
have colonized the nasal and upper respira-
tory systems, known as “commensal flora,”
and considered un-harmful and asympto-
matic in these locations. These bacteria, upon
weakening of host defenses by influenza, can
migrate down the respiratory tract and ex-
pand in new bacterially na￯ve niches, where
they can become harmful to the host. The
most common complicating bacterial agents
include Staphylococcus aureus, Streptococ-
cus pneumonia, and haemophilus influenzae,
among others [7-10]. In fact, due to high
rates of bacterial complications, haemophilus
influenzae was given its name upon discov-
ery because researchers originally thought it
was the cause of flu-like symptoms (viruses
had yet to be discovered) [11]. 
Upon the onset of viral infection, sev-
eral processes occur that researchers believe
may make the respiratory system suscepti-
ble  to  bacterial  infiltration.  One  leading
thought holds that influenza neuraminidase,
the viral enzyme responsible for removing
sialic acids from host cell surfaces and viral
anchoring proteins, thus allowing new virion
release from cells, also may remove sialic
acids that usually block bacterial anchor
sites, allowing new niches for bacteria to
grow  [12,13].  In  concurrent  coinfection,
bacterial expansion is typically more ele-
vated than in singular infection alone, po-
tentially because of increased binding sites
[13]. Host parameters also may aid in prim-
ing sensitivity to coinfection. Recent reports
indicate that specific host signaling mole-
cules from the antiviral response may up-
regulate  host  bacterial-sensing  signaling
components  [14].  Virtually  all  cells  are
equipped with specific receptors known as
pattern-recognition receptors (PRRs) to de-
tect  the  presence  of  pathogens  such  as
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produce cytokines, host proteins secreted for
intercellular communication. Upon receptor
binding of these cytokines, receiving cells
are shown to increase expression of bacter-
ial-sensing PRRs such as the NOD proteins,
allowing for amplified immune responses
seen in coinfection [14]. It is typical in con-
current coinfection that combined infection
is amplified often in pathogen amount and
immune response as compared to singular
infections [14-16].
Concurrent  coinfection  causes  some
difficulty in treating either infection. While
antiviral treatment helps reduce viral bur-
den, the efficacy of many of these treatments
against concurrent bacterial infection is still
unknown [17], and treatment to counter host
pro-inflammatory molecules that may ame-
liorate flu symptoms may have unknown
consequences on bacterial infection [16].
These interactions also can work against the
underlying viral infection, exemplified with
the use of glucocorticoids, hormones pro-
duced by the host to dampen inflammation.
Recent work has demonstrated that blocking
flu-induced glucocorticoid production helps
block bacterial spread by maintaining active
inflammation [18]. However, this treatment
has negative consequences on viral infec-
tion, allowing for more host pathology [18].
Preventive treatment such as flu vaccination
seems the immediate option currently avail-
able, and antibiotics and antivirals are often
prescribed after coinfection [19].  
Secondary/sequential infection: 
respiratory viruses + commensal bacteria
Two  infections  also  do  not  need  to
overlap directly in time in order to affect
each other. Bacterial pneumonia in con-
junction  with  influenza  can  occur  soon
after viral clearance, a situation slightly dif-
ferent from concurrent infection. This is
also seen in other respiratory coinfections,
such as bacterial infection leading to ear in-
fections, known as otitis media [5]. Otitis
media is especially common in small chil-
dren  and  usually  caused  by  bacterial  S.
pneumoniae or  H.  influenzae following
coronavirus,  respiratory  syncytial  virus
(RSV), or adenoviral infection [5,20]. Like
bacterial pneumonia and influenza, otitis
media can often be a concurrent polymi-
crobial infection [21].
Focusing on bacterial pneumonia asso-
ciated with influenza infection, there are
various differences noted in secondary bac-
terial infection versus concurrent [7]. These
include altered cytokine expression patterns
in vivo, especially an increase in immune-
suppressive IL-10 versus pro-inflammatory
interferons as seen in concurrent infections
[22].  Moreover,  a  common  feature  seen
soon after clearance of initial infection is
the suppression of toll-like receptor (TLR)
signaling, also seen post-influenza infection
[23].  The  TLR  family  of  receptors  is  a
member of the previously described PRRs
and includes receptors to virus and bacterial
products. This is distinct from concurrent
infection, where active TLR signaling con-
tinues. In this case, TLR responsiveness is
decreased, thereby having the immune sys-
tem respond less actively than usual upon
bacterial infection, potentially allowing the
bacteria to take hold without immune de-
terrent [23].
In the situation of delayed secondary in-
fection, there are both similar difficulties with
treatment and differences from concurrent in-
fection. In this case, there is no direct inter-
action  with  the  virus.  Instead,  one  must
consider the condition of the host tissue post
viral infection, which may be experiencing
immune dampening and increased thresholds
for activating signals. Therefore, giving im-
mune-stimulating agents to assist in bacterial
clearance may not be as effective as in iso-
lated infection. Giving direct antibiotics can
likely help, but giving specific cytokines to
help boost immunity may not [7]. While most
current treatments work through direct assault
on the pathogen, another useful angle may be
to target ways to help return tissue homeosta-
sis, such as helping induce angiogenesis or
increased barrier protections such as mucus
production [24]. Further study into the tim-
ing of returned immune sensitivity and tissue
homeostasis will be especially important for
these delayed situations of secondary coin-
fection. 
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A third scenario that allows for coin-
fection is an already underlying chronic in-
fection. HIV is a systemic viral infection that
infects and destroys both innate and adap-
tive immune cells [25]. Through its manip-
ulation  of  the  immune  system,  HIV  can
disarm several defensive strategies of the
host [26]. Upon exposure, HIV virus infects
both T cells and macrophages at different
stages of the infection, leading to a net loss
in both of these immune defense cell types.
Moreover, through the loss of these cells, T
cells can no longer help activate B cells, the
cells responsible for producing protective
antibodies, proteins that can neutralize virus
and help remove virally infected cells. Loss
of macrophages also breaks a crucial step in
the activation of other immune responses as
well, as macrophages serve as important ini-
tial sensors of infection [25,26]. Continual
immune activation also allows for charac-
teristic changes that are different from acute
infection,  including  non-antigen-specific
polyclonal B cell activation [27], enhanced
T  cell  turnover  [28],  and  maintained  in-
creased levels of inflammatory cyto- and
chemokines [26,29].
This active immuno-suppression and
destruction of immune cells is continually
ongoing during an HIV infection, allowing
for the onset of another infection in an al-
ready weakened host. Complicating agents
that take hold during HIV infection are often
opportunistic, in that under “normal” im-
mune-competent conditions, these agents
would not be infective. These agents are
often already a part of our normal flora, ei-
ther commensal or suppressed when im-
mune-competent, and include agents such as
salmonella, toxoplasma, herpes infection,
tuberculosis,  candida  albicans,  and  cy-
tomegalovirus. For sake of concision, this
review will focus on tuberculosis as the ex-
ample  of  HIV  coinfection.  Tuberculosis,
caused by bacterium Mycobacterium tuber-
culosis (Mtb), has seen a recent rise in global
infection rates predominantly due to con-
current infection with HIV [30]. Patients
who  previously  have  been  infected  by
asymptomatic Mtb (about 90 percent of 2
billion Mtb infections worldwide) can now
see a reawakening of infection due to weak-
ened immune state from HIV [31]. 
Opportunistic infections during HIV in-
fection are often described as secondary in-
fections, but HIV is still ongoing. This is an
important distinction because it means a
continual immune response and immune ac-
tivation remain, rather than a delayed im-
mune dampening following the resolution of
an initial infection. There are several dilem-
mas for treatment of concurrent coinfection
with an underlying chronic infection. A re-
cent study has highlighted the potential for
HIV to selectively destroy a class of T cells
activated against Mtb among its targeted ac-
tivated CD4+ T cells, thereby removing the
adaptive response against Mtb [32]. In that
light,  any  immune-enhancing  treatment
against Mtb that acts through the adaptive
response would likely be less effective in
HIV+ patients. Conversely, if left untreated,
preliminary studies indicate that tuberculosis
may expedite the course of HIV infection,
showing associations with increased HIV
replication rates and enhanced viral entry
into host cells in vitro [6]. Underlying HIV
infection  can  modulate  Mtb  infection  to
allow further dissemination of the bacteria,
where HIV+ patients have higher rates of
extra-pulmonary Mtb than those who are
HIV-  [6,33].  Luckily,  conventional  anti-
retroviral treatment of HIV also helps lower
levels of Mtb infection [6]. The improved
understanding of how these infections mod-
ulate each other allows more specific deter-
mination  of  appropriate  therapeutic  and
preventive treatments.
future research
From these examples, it is clear that the
study of individual infectious agents against
a “clean slate” host may be insufficient to
fully capture the underlying issues of phys-
iological infection. Additional focus on the
tissue state of the host before, during, and
after common “priming” infections such as
respiratory  viral  infections  or  systemic
chronic infections will help clarify the state
of host tissue environment upon contraction
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vidual infections, it is important that scien-
tists  follow  through  after  infectious
clearance to determine the time delay and
processes involved in returning host tissue
to homeostasis. 
Respiratory viral infections are notori-
ous for secondary complications, but we still
do not understand the unique relationships
between initial viral infections and second-
ary bacterial complicators. Why does in-
fluenza  allow  for  complicating  bacterial
pneumonia, but RSV more commonly com-
plicates bacterial otitis media? Both second-
ary infections are often caused by the host’s
own commensal nasal flora, but the main
agents differ in co-viruses as well as where
they  colonize  in  their  pathological  state.
Clearer delineation of tissue alterations dur-
ing and following viral infection can help
clarify the logic behind these pairings. 
How an infectious agent behaves may
differ depending on the host environment it
finds itself within. It is reasonable to imag-
ine that a secondary infection entering into
an environment already inflamed with in-
creased  cytokine  levels  and  an  ongoing
adaptive response may activate a different
collection of virulence genes, infect differ-
ent cell types and tissues, or use different
strategies than it would upon infecting a
“clean slate.” This type of difference is seen
in complicating cases of tuberculosis sec-
ondary to HIV infection, in which Mtb can
more easily spread to extra-pulmonary sites.
In this case, it becomes equally important to
study Mtb infection within an already sup-
pressed immune response as separate from
Mtb infection alone, because isolated infec-
tion may not accurately predict how to treat
complicated Mtb for HIV+ patients. 
conclusIon
Studies of infectious agents can be per-
formed in various levels of “complication”
and all are important. Basic in vitro studies
are important to understand the exact func-
tioning of individual components of the in-
fectious  agent  and  allow  scientists  to
delineate requirements and interactions of
different components that would be too ob-
scured in more complicated in vivo settings.
Oftentimes, in vivo studies may not even be
possible when we do not know how infec-
tion is established, relevant hosts may not be
available for study, agents may not be infec-
tious for common laboratory animals, or un-
derstanding of how chronic infections are
maintained may not be well enough under-
stood to recapitulate as of yet. However, es-
pecially for key killers such as acute and
chronic viral infections, additional research
is starting and should be continued in the
settings of more complicated polymicrobial
infections. This can be examined both in
vitro and in vivo and may help clarify what
activities, both from the pathogen and the
host, allow for these increased susceptibili-
ties and how we can better address these in
preventive and therapeutic care. 
On a scientific level, these studies also
will increase our understanding of the inter-
actions between different infectious agents
and how they may aid each other in their life
cycles within the complex setting of a larger
host. Interaction with another infectious agent
during one’s own natural infectious cycle can
have large alterations on that agent that we do
not yet understand. As our technological ca-
pacities expand, so does our ability to delin-
eate the complex interactions between living
things, and we can step up from studies of
one-to-one relationships between organisms
to combinatorially and web-like interactions,
slowly progressing toward a more full, phys-
iologically accurate understanding. 
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